Immunomodulatory effects of opioids

Journal of Veterinary Emergency and Critical Care

Volumn 20, Issue 4, 2010, Pages 376-385

  Odunayo, Adesola ^a   Dodam, John R ^a   Kerl, Marie E ^a   DeClue, Amy E ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

HPA axis; Immunosuppression; Intravenous drug users; Morphine; Sepsis

Indexed keywords

IMMUNOLOGIC FACTOR; NARCOTIC AGENT; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ADDICTION; ANIMAL; ANIMAL DISEASE; DRUG EFFECT; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE; METHODOLOGY; NATURAL KILLER CELL; REVIEW;

ANALGESICS, OPIOID; ANIMALS; CRITICAL CARE; HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; KILLER CELLS, NATURAL; NARCOTIC ANTAGONISTS; NARCOTICS; SUBSTANCE-RELATED DISORDERS;

ANIMALIA;

EID: 77955973854     PISSN: 14793261     EISSN: 14764431     Source Type: Journal    
DOI: 10.1111/j.1476-4431.2010.00561.x     Document Type: Review

References (145)

1. Dhawan BN, Cesselin F, Raghubir R. International union of pharmacology. Xii. Classification of opioid receptors. Pharmacol Rev 1996, 48((4)):567-592.
2. Carr DB, Goudas LC. Acute pain. Lancet 1999, 353((9169)):2051-2058.
3. Schofferman J. Long-term opioid analgesic therapy for severe refractory lumbar spine pain. Clin J Pain 1999, 15((2)):136-140.
4. Weinert C, Kethireddy S, Roy S. Opioids and infections in the intensive care unit should clinicians and patients be concerned? J Neuroimmune Pharmacol 2008, 3((4)):218-229.
5. Stein C, Lang LJ. Peripheral mechanisms of opioid analgesia. Curr Opin Pharmacol 2009, 9((1)):3-8.
6. Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain 2002, 18((4)):S3-S13.
7. Lopez A, Salomé L. Membrane functional organisation and dynamic of μ-opioid receptors. Cell Mol Life Sci 2009, 66((13)):2093-2018.
8. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem 2004, 73((1)):953-990.
9. Janson W, Stein C. Peripheral opioid analgesia. Curr Pharm Biotechnol 2003, 4((4)):270-274.
10. Barry U, Zuo Z. Opioids: old drugs for potential new applications. Curr Pharm Des 2005, 11((10)):1343-1350.
11. Pasternak GW. Multiple opiate receptors: Déjà vu all over again. Neuropharmacology 2004, 47((suppl 1)):312-323.
12. Goodman Allan J, Le Bourdonnec B, Dolle Roland E. Mu opioid receptor antagonists: recent developments. ChemMedChem 2007, 2((11)):1552-1570.
13. McCarthy L, Wetzel M, Sliker JK. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend 2001, 62((2)):111-123.
14. Hilburger ME, Adler MW, Truant AL. Morphine induces sepsis in mice. J Infect Dis 1997, 176((1)):183-188.
15. McQuay H. Opioids in pain management. Lancet 1999, 353((9171)):2229-2232.
16. Stanway G, Taylor PM, Brodbelt DC. A preliminary investigation comparing pre-operative morphine and buprenorphine for postoperative analgesia and sedation in cats. Vet Anaesth Analg 2002, 29((1)):29-35.
17. Walsh SL, Preston KL, Bigelow GE. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 1995, 274((1)):361-372.
18. Lawlor P, Turner K, Hanson J. Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain 1997, 72((1-2)):79-85.
19. Eddy NB, Lee LE. The analgesic equivalence to morphine and relative side action liability of oxymorphone (4-hydroxydihydromorphinone). J Pharmacol Exp Ther 1959, 125((2)):116-121.
20. Paix A, Coleman A, Lees J. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain 1995, 63((2)):263-269.
21. Collins RJ, Weeks JR. Relative potency of codeine, methadone and dihydromorphinone to morphine in self-maintained addict rats. Naunyn Schmiedebergs Arch Pharmacol 1965, 249((6)):509-514.
22. Pereira J, Lawlor P, Vigano A. Equianalgesic dose ratios for opioids: a critical review and proposals for long-term dosing. J Pain Symptom Manage 2001, 22((2)):672-687.
23. Roy S, Barke RA, Loh HH. Mu-opioid receptor-knockout mice: role of mu-opioid receptor in morphine mediated immune functions. Brain Res Mol Brain Res 1998, 61((1-2)):190-194.
24. Eisenstein TK, Hilburger ME. Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations. J Neuroimmunol 1998, 83((1-2)):36-44.
25. Bidlack JM. Detection and function of opioid receptors on cells from the immune system. Clin Diagn Lab Immunol 2000, 7((5)):719-723.
26. Sacerdote P. Opioid-induced immunosuppression. Curr Opin Support Palliat Care 2008, 2((1)):14-18.
27. Budd K. Pain management: is opioid immunosuppression a clinical problem? Biomed Pharmacother 2006, 60((7)):310-317.
28. Sacerdote P, Bianchi M, Gaspani L. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg 2000, 90((6)):1411-1414.
29. Martucci C, Panerai AE, Sacerdote P. Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain 2004, 110((1-2)):385-392.
30. Sacerdote P. Opioids and the immune system. Palliat Med 2006, 20((8 suppl)):9-15.
31. Gomez-Flores R, Weber RJ. Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaqueductal gray. Immunopharmacology 2000, 48((2)):145-156.
32. Wang J, Charboneau R, Balasubramanian S. The immunosuppressive effects of chronic morphine treatment are partially dependent on corticosterone and mediated by the μ-opioid receptor. J Leukoc Biol 2002, 71((5)):782-790.
33. Paola S, Barbara M, Paolo M. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol 1997, 121((4)):834-840.
34. Franchi S, Panerai AE, Sacerdote P. Buprenorphine ameliorates the effect of surgery on hypothalamus-pituitary-adrenal axis, natural killer cell activity and metastatic colonization in rats in comparison with morphine or fentanyl treatment. Brain Behav Immun 2007, 21((6)):767-774.
35. Saurer TB, Carrigan KA, Ijames SG. Suppression of natural killer cell activity by morphine is mediated by the nucleus accumbens shell. J Neuroimmunol 2006, 173((12)):3-11.
36. Beilin B, Shavit Y, Hart J. Effects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the perioperative period. Anesth Analg 1996, 82((3)):492-497.
37. Forget P, Collet V, Lavand'homme P. Does analgesia and condition influence immunity after surgery? Effects of fentanyl, ketamine and clonidine on natural killer activity at different ages. Eur J Anaesthesiol 2010, 27((3)):233-240.
38. Bilfinger TV, Fimiani C, Stefano GB. Morphine's immunoregulatory actions are not shared by fentanyl. Int J Cardiol 1998, 64((suppl 1)):S61-S66.
39. Pechnick RN. Effects of opioids on the hypothalamo-pituitary-adrenal axis. Annu Rev Pharmacol Toxicol 1993, 33((1)):353-382.
40. Martin-Kleiner I, Gabrilovac J. Naloxone modulates nk-cell activity of human peripheral blood lymphocytes like an opioid agonist. Immunopharmacol Immunotoxicol 1993, 15((2-3)):179-197.
41. Sacerdote P, Manfredi B, Gaspani L. The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in balb/cj mice. Blood 2000, 95((6)):2031-2036.
42. Wei G, Moss J, Yuan C-S. Opioid-induced immunosuppression: is it centrally mediated or peripherally mediated? J Pharm Biomed Anal 2003, 65((11)):1761-1766.
43. Mellon RD, Bayer BM. Evidence for central opioid receptors in the immunomodulatory effects of morphine: review of potential mechanism(s) of action. J Neuroimmunol 1998, 83((1-2)):19-28.
44. Nelson CJ, Schneider GM, Lysle DT. Involvement of central mu- but not delta- or kappa-opioid receptors in immunomodulation. Brain Behav Immun 2000, 14((3)):170-184.
45. Gaveriaux-Ruff C, Matthes HW, Peluso J. Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene. Proc Natl Acad Sci USA 1998, 95((11)):6326-6330.
46. Hall DM, Suo JL, Weber RJ. Opioid mediated effects on the immune system: sympathetic nervous system involvement. J Neuroimmunol 1998, 83((1-2)):29-35.
47. Shavit Y, Lewis JW, Terman GW. Opioid peptides mediate the suppressive effect of stress on natural killer cell cytotoxicity. Science 1984, 223((4632)):188-190.
48. Hernandez M, Flores L, Bayer B. Immunosuppression by morphine is mediated by central pathways. J Pharmacol Exp Ther 1993, 267((3)):1336-1341.
49. Shavit Y, Depaulis A, Martin FC. Involvement of brain opiate receptors in the immune-suppressive effect of morphine. Proc Natl Acad Sci U S A 1986, 83((18)):7114-7117.
50. Mellon RD, Bayer BM. Role of central opioid receptor subtypes in morphine-induced alterations in peripheral lymphocyte activity. Brain Res 1998, 789((1)):56-67.
51. Liang-Suo J, Gomez-Flores R, Weber RJ. Immunosuppression induced by central action of morphine is not blocked by mifepristone (ru 486). Life Sci 2002, 71((22)):2595-2602.
52. Weber R, Pert A. The periaqueductal gray matter mediates opiate-induced immunosuppression. Science 1989, 245((4914)):188-190.
53. Nelson CJ, Schneider GM, Lysle DT. Involvement of central [mu]- but not [delta]- or [kappa]-opioid receptors in immunomodulation. Brain Behav Immun 2000, 14((3)):170-184.
54. Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther 2004, 11((5)):354-365.
55. Roy S, Wang J, Kelschenbach J. Modulation of immune function by morphine: implications for susceptibility to infection. J Neuroimmune Pharmacol 2006, 1((1)):77-89.
56. Alonzo NC, Bayer BM. Opioids, immunology, and host defenses of intravenous drug abusers. Infect Dis Clin North Am 2002, 16((3)):553-569.
57. Flores LR, Hernandez MC, Bayer BM. Acute immunosuppressive effects of morphine: lack of involvement of pituitary and adrenal factors. J Pharmacol Exp Ther 1994, 268((3)):1129-1134.
58. Bryant HU, Bernton EW, Kenner JR. Role of adrenal cortical activation in the immunosuppressive effects of chronic morphine treatment. Endocrinology 1991, 128((6)):3253-3258.
59. Flores LR, Wahl SM, Bayer BM. Mechanisms of morphine-induced immunosuppression: effect of acute morphine administration on lymphocyte trafficking. J Pharmacol Exp Ther 1995, 272((3)):1246-1251.
60. Freier DO, Fuchs BA. A mechanism of action for morphine-induced immunosuppression: corticosterone mediates morphine-induced suppression of natural killer cell activity. J Pharmacol Exp Ther 1994, 270((3)):1127-1133.
61. Spengler R, Chensue S, Giacherio D. Endogenous norepinephrine regulates tumor necrosis factor-alpha production from macrophages in vitro. J Immunol 1994, 152((6)):3024-3031.
62. Carr DJ, Gebhardt BM, Paul D. Alpha adrenergic and mu-2 opioid receptors are involved in morphine- induced suppression of splenocyte natural killer activity. J Pharmacol Exp Ther 1993, 264((3)):1179-1186.
63. Flores LR, Dretchen KL, Bayer BM. Potential role of the autonomic nervous system in the immunosuppressive effects of acute morphine administration. Eur J Pharmacol 1996, 318((2-3)):437-446.
64. Fecho K, Dykstra LA, Lysle DT. Evidence for beta adrenergic receptor involvement in the immunomodulatory effects of morphine. J Pharmacol Exp Ther 1993, 265((3)):1079-1087.
65. Radulovic J, Miljevic C, Djergovic D. Opioid receptor-mediated suppression of humoral immune response in vivo and in vitro: involvement of kappa opioid receptors. J Neuroimmunol 1995, 57((1-2)):55-62.
66. Rojavin M, Szabo I, Bussiere JL. Morphine treatment in vitro or in vivo decreases phagocytic functions of murine macrophages. Life Sci 1993, 53((12)):997-1006.
67. Chao CC, Hu S, Shark KB. Activation of mu opioid receptors inhibits microglial cell chemotaxis. J Pharmacol Exp Ther 1997, 281((2)):998-1004.
68. Bussiere J, Adler M, Rogers T. Cytokine reversal of morphine-induced suppression of the antibody response. J Pharmacol Exp Ther 1993, 264((2)):591-597.
69. Bhargava HN, Thomas PT, Thorat S. Effects of morphine tolerance and abstinence on cellular immune function. Brain Res 1994, 642((1-2)):1-10.
70. Roy S, Ramakrishnan S, Loh HH. Chronic morphine treatment selectively suppresses macrophage colony formation in bone marrow. Eur J Pharmacol 1991, 195((3)):359-363.
71. Szabo I, Rojavin M, Bussiere JL. Suppression of peritoneal macrophage phagocytosis of Candida albicans by opioids. J Pharmacol Exp Ther 1993, 267((2)):703-706.
72. Sharp BM, Keane WF, Suh HJ. Opioid peptides rapidly stimulate superoxide production by human polymorphonuclear leukocytes and macrophages. Endocrinology 1985, 117((2)):793-795.
73. Bhat RS, Bhaskaran M, Mongia A. Morphine-induced macrophage apoptosis: oxidative stress and strategies for modulation. J Leukoc Biol 2004, 75((6)):1131-1138.
74. Fecho K, Maslonek KA, Coussons-Read ME. Macrophage-derived nitric oxide is involved in the depressed concanavalin a responsiveness of splenic lymphocytes from rats administered morphine in vivo. J Immunol 1994, 152((12)):5845-5852.
75. Koff WC, Dunegan MA. Modulation of macrophage-mediated tumoricidal activity by neuropeptides and neurohormones. J Immunol 1985, 135((1)):350-354.
76. Singhal PC, Sharma P, Kapasi AA. Morphine enhances macrophage apoptosis. J Immunol 1998, 160((4)):1886-1893.
77. Yeager MP, Colacchio TA, Yu CT. Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology 1995, 83((3)):500-508.
78. Bayer BM, Daussin S, Hernandez M. Morphine inhibition of lymphocyte activity is mediated by an opioid dependent mechanism. Neuropharmacology 1990, 29((4)):369-374.
79. Lysle DT, Hoffman KE, Dykstra LA. Evidence for the involvement of the caudal region of the periaqueductal gray in a subset of morphine-induced alterations of immune status. J Pharmacol Exp Ther 1996, 277((3)):1533-1540.
80. Ishikawa M, Tanno K, Kamo A. Enhancement of tumor growth by morphine and its possible mechanism in mice. Biol Pharm Bull 1993, 16((8)):762-766.
81. Yeager MP, Colacchio TA. Effect of morphine on growth of metastatic colon cancer in vivo. Arch Surg 1991, 126((4)):454-456.
82. Sasamura T, Nakamura S, Iida Y. Morphine analgesia suppresses tumor growth and metastasis in a mouse model of cancer pain produced by orthotopic tumor inoculation. Eur J Pharmacol 2002, 441((3)):185-191.
83. Roy S, Loh H. Effects of opioids on the immune system. Neurochem Res 1996, 21((11)):1375-1386.
84. Roy S, Balasubramanian S, Sumandeep S. Morphine directs T cells toward T differentiation. Surgery 2001, 130((2)):304-309.
85. Roy S, Wang J, Gupta S. Chronic morphine treatment differentiates t helper cells to th2 effector cells by modulating transcription factors gata 3 and t-bet. J Neuroimmunol 2004, 147((1-2)):78-81.
86. Greeneltch KM, Kelly-Welch AE, Shi Y. Chronic morphine treatment promotes specific th2 cytokine production by murine t cells in vitro via a fas/fas ligand-dependent mechanism. J Immunol 2005, 175((8)):4999-5005.
87. Bryant HU, Bernton EW, Holaday JW. Immunosuppressive effects of chronic morphine treatment in mice. Life Sci 1987, 41((14)):1731-1738.
88. Roy S, Charboneau R, Barke R. Role of mu-opioid receptor in immune function. Neuroimmune Circuits, Drugs Abuse, Infect Dis 2001, 493:117-126.
89. Belkowski SM, Alicea C, Eisenstein TK. Inhibition of interleukin-1 and tumor necrosis factor-alpha synthesis following treatment of macrophages with the kappa opioid agonist u50, 488h. J Pharmacol Exp Ther 1995, 273((3)):1491-1496.
90. Roy S, Cain KJ, Chapin RB. Morphine modulates nf[kappa]b activation in macrophages. Biochem Biophys Res Commun 1998, 245((2)):392-396.
91. Peterson P, Sharp B, Gekker G. Opioid-mediated suppression of cultured peripheral blood mononuclear cell respiratory burst activity. J Immunol 1987, 138((11)):3907-3912.
92. Wang J, Barke RA, Charboneau R. Morphine negatively regulates interferon-gamma promoter activity in activated murine t cells through two distinct cyclic amp-dependent pathways. J Biol Chem 2003, 278((39)):37622-37631.
93. Peng X, Mosser DM, Adler MW. Morphine enhances interleukin-12 and the production of other pro-inflammatory cytokines in mouse peritoneal macrophages. J Leukoc Biol 2000, 68((5)):723-728.
94. Bhaskaran M, Reddy K, Sharma S. Morphine-induced degradation of the host defense barrier: role of macrophage injury. J Infect Dis 2001, 184((12)):1524-1531.
95. Lucas AN, Firth AM, Anderson GA. Comparison of the effects of morphine administered by constant-rate intravenous infusion or intermittent intramuscular injection in dogs. J Am Vet Med Assoc 2001, 218((6)):884-891.
96. Tseng CS, Tso HS. Effects of opioid agonists and opioid antagonists in endotoxic shock in rats. Anaesthesiologica Sinica 1993, 31((1)):1-8.
97. Ocasio FM, Jiang Y, House SD. Chronic morphine accelerates the progression of lipopolysaccharide-induced sepsis to septic shock. J Neuroimmunol 2004, 149((1-2)):90-100.
98. Tsai S-M, Lin M-T, Wang J-J. Pyrogens enhance beta endorphin release in hypothalamus and trigger fever that can be attenuated by buprenorphine. J Pharmacol Sci 2003, 93((2)):155-162.
99. Donaldson MD, Vesey CJ, Wilks M. Beneficial effects of buprenorphine (a partial opiate agonist) in porcine Escherichia coli septicaemia: a comparison with naloxone. Circ Shock 1988, 25((3)):209-221.
100. Lin S-L, Lee Y-M, Chang H-Y. Effects of naltrexone on lipopolysaccharide-induced sepsis in rats. J Biomed Sci 2005, 12((2)):431-440.
101. Greeneltch KM, Haudenschild CC, Keegan AD. The opioid antagonist naltrexone blocks acute endotoxic shock by inhibiting tumor necrosis factor-[alpha] production. Brain Behav Immun 2004, 18((5)):476-484.
102. Boeuf B, Gauvin F, Guerguerian AM. Therapy of shock with naloxone: a meta-analysis. Crit Care Med 1998, 26((11)):1910-1916.
103. Peters WP, Johnson MW, Friedman PA. Pressor effect of naloxone in septic shock. The Lancet 1981, 1((8219)):529-532.
104. Rock P, Silverman H, Plump D. Efficacy and safety of naloxone in septic shock. Crit Care Med 1985, 13((1)):28-33.
105. Hussey HH, Katz S. Infections resulting from narcotic addiction; report of 102 cases. Am J Med 1950, 9((2)):186-193.
106. Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev 2003, 16((2)):209-219.
107. Reichman LB, Felton CP, Edsall JR. Drug dependence, a possible new risk factor for tuberculosis disease. Arch Intern Med 1979, 139((3)):337-339.
108. Des Jarlais DC. Potential cofactors in the outcomes of HIV infection in intravenous drug users. NIDA Res Monogr 1991, 109:115-123.
109. De Paoli P, Reitano M, Battistin S. Immunological abnormalities in intravenous drug abusers and relationship to the prolonged generalized lymphadenopathy syndrome in Italy. Clin Exp Immunol 1986, 64((3)):451-456.
110. Cooper O, Brown T, Dobs A. Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease. Clin Infect Dis 2003, 37((s2)):S132-S136.
111. Nair MP, Schwartz SA, Polasani R. Immunoregulatory effects of morphine on human lymphocytes. Clin Diagn Lab Immunol 1997, 4((2)):127-132.
112. Peterson PK, Sharp BM, Gekker G. Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS 1990, 4((9)):869-873.
113. Kitanaka N, Sora I, Kinsey S. No heroin or morphine 6β-glucuronide analgesia in μ-opioid receptor knockout mice. Eur J Pharmacol 1998, 355((1)):R1-R3.
114. Lokensgard JR, Gekker G, Peterson PK. κ-opioid receptor agonist inhibition of HIV-1 envelope glycoprotein-mediated membrane fusion and CXCR4 expression on CD4+ lymphocytes. Biochem Pharmacol 2002, 63((6)):1037-1041.
115. Hubbard RL, Marsden ME, Cavanaugh E. Role of drug-abuse treatment in limiting the spread of aids. Rev Infect Dis 1988, 10((2)):377-384.
116. Peterson PK, Gekker G, Lokensgard JR. κ-opioid receptor agonist suppression of HIV-1 expression in CD4+lymphocytes. J Pharm Biomed Anal 2001, 61((9)):1145-1151.
117. Weber R, Ledergerber B, Opravil M. Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone. BMJ 1990, 301((6765)):1362-1365.
118. Schwacha MG, McGwin JG, Hutchinson CB. The contribution of opiate analgesics to the development of infectious complications in burn patients. Am J Surg 2006, 192((1)):82-86.
119. Biki B, Mascha E, Moriarty DC. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology 2008, 109((2)):180-187.
120. Bonnet F, Bilaine J, Lhoste F. Naloxone therapy of human septic shock. Crit Care Med 1985, 13((11)):972-975.
121. Hellyer PW, Bai L, Supon J. Comparison of opioid and alpha-2 adrenergic receptor binding in horse and dog brain using radioligand autoradiography. Vet Anaesth Analg 2003, 30((3)):172-182.
122. Clark WG, Ponder SW. Thermoregulatory effects of (d-ala2)-methionine-enkephalinamide in the cat. Evidence for multiple naloxone-sensitive opioid receptors. Brain Res Bull 1980, 5((4)):415-420.
123. Castanas E, Bourhim N, Giraud P. Interaction of opiates with opioid binding sites in the bovine adrenal medulla: Ii. Interaction with kappa sites. J Neurochem 1985, 45((3)):688-699.
124. Bouaziz H, Tong C, Yoon Y. Intravenous opioids stimulate norepinephrine and acetylcholine release in spinal cord dorsal horn: systematic studies in sheep and an observation in a human. Anesthesiology 1996, 84((1)):143-154.
125. Clark JD, Shi X, Li X. Morphine reduces local cytokine expression and neutrophil infiltration after incision. Mol Pain 2007, 3((1)):28.
126. Bilfinger TV, Kushnerik V, Bundz S. Evidence for morphine downregulating immunocytes during cardiopulmonary bypass in a porcine model. Int J Cardiol 1996, 53((suppl 1)):S39-S46.
127. Barr MC, Huitron-Resendiz S, Sanchez-Alavez M. Escalating morphine exposures followed by withdrawal in feline immunodeficiency virus-infected cats: a model for HIV infection in chronic opiate abusers. Drug Alcohol Depend 2003, 72((2)):141-149.
128. McLachlan E. Recognizing pain. Am J Nurs 1974, 74((3)):496-497.
129. O'Gara PT. The hemodynamic consequences of pain and its management. J Intensive Care Med 1988, 3((1)):3-5.
130. Stucky CL, Gold MS, Zhang X. Mechanisms of pain. Natl Acad Sci USA 2001, 98((21)):11845-11846.
131. Pergolizzi J, Böger RH, Budd K. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008, 8((4)):287-313.
132. DeClue AE, Cohn LA, Lechner ES. Effects of subanesthetic doses of ketamine on hemodynamic and immunologic variables in dogs with experimentally induced endotoxemia. Am J Vet Res 2008, 69((2)):228-232.
133. Furst SM, Komocsar WJ, Khan KN. Screening new drugs for immunotoxic potential: I. Assessment of the effects of conventional nonsteroidal anti-inflammatory drugs and selective cox-2 inhibitors on in vitro and in vivo phagocytic activity. J Immunotoxicol 2005, 1((3)):149-158.
134. Toth PD, Hamburger SA, Hastings GH. Benoxaprofen attenuation of lethal canine endotoxic shock. Circ Shock 1985, 15((2)):89-103.
135. Son KA, Kang JH, Yang MP. Ketamine inhibits the phagocytic responses of canine peripheral blood polymorphonuclear cells through the upregulation of prostaglandin E2 in peripheral blood mononuclear cells in vitro. Res Vet Sci 2009, 87((1)):41-46.
136. Schmid RL, Sandler AN, Katz J. Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes. Pain 1999, 82((2)):111-125.
137. Smith LJ, Shih A, Miletic G. Continual systemic infusion of lidocaine provides analgesia in an animal model of neuropathic pain. Pain 2002, 97((3)):267-273.
138. Mathews KA. Non-steroidal anti-inflammatory analgesics: a review of current practice. J Vet Emerg Crit Care 2002, 12((2)):89-97.
139. Mathews KA. Pain assessment and general approach to management. Vet Clin North Am Small Anim Pract 2000, 30((4)):729-755. v
140. Corletto F. Multimodal and balanced analgesia. Vet Res Commun 2007, 31:59-63.
141. Jones RS. Epidural analgesia in the dog and cat. Vet J 2001, 161((2)):123-131.
142. Dhawan BN, Cesselin F, Raghubir R. International union of pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 1996, 48((4)):567-592.
143. House RV, Thomas PT, Bhargava HN. In vitro evaluation of fentanyl and meperidine for immunomodulatory activity. Immunol Lett 1995, 46((1-2)):117-124.
144. Messmer UK, Reed UK, Brune B. Bcl-2 protects macrophages from nitric oxide-induced apoptosis. J Biol Chem 1996, 271((33)):20192-20197.
145. Roberts D, Hall K, Dobson K. Effects of prolonged naloxone infusion in septic shock. The Lancet 1988, 332((8613)):699-702.